Health Care
Commentary
Learn more about how price fixing stifles innovation
New Schizophrenia Drug Represents Promise Of Pharmaceutical Innovation
Late last month, the U.S. Food and Drug Administration approved Bristol Myers Squibb’s KarXT, a treatment for schizophrenia. The drug, which will be marketed under the brand name Cobenfy, is promising not just because it is effective at treating the debilitating mental health condition. It also seems not to have the potentially harmful side ...
Commentary
Learn more about healthcare reform
Vance’s Critics Wrong: No Need to Fear High-Risk Pools
Following the recent vice-presidential debate, Sen. J.D. Vance, R-Ohio, continues to face attacks on his ideas for covering people with pre-existing conditions. Vance’s critics call his proposal — which would separate out sicker patients into a separate high-risk insurance pool — inhumane and impractical. As Arthur Caplan, the head of medical ethics at NYU ...
Commentary
Learn more about how price controls are driving physician shortages
Price Controls Are Harming Doctors
Whether its pharmaceuticals or health insurance, Vice President Kamala Harris appears to have only one healthcare policy – impose price controls. The untenable financial position of many doctors and private doctor practices due to tightening Medicare reimbursement rates exemplifies the folly of her preferred approach. As I document in a recent ...
Commentary
Learn how Vance's suggestion would benefit consumers
Vance’s Argument on Preexisting Conditions a Sure Winner
When asked how people with pre-existing conditions would fare under a Trump-Vance administration during last week’s vice-presidential debate, Sen. J.D. Vance, R-Ohio, was unequivocal. “Well, of course, we’re going to cover Americans with pre-existing conditions.” The question was prompted by Vance’s statement last month that the Republican ticket would consider creating different risk ...
340B. drug pricing
How The Hospital Industrial Complex Robs Poor Patients
Pharmaceutical leader Johnson & Johnson recently unleashed a firestorm in Washington after it proposed a change to how it offers discounted prices on two drugs in a little-known, but enormous, federal program that’s hurting the low-income patients it was created to help. That program, known as the “340B Drug Pricing Program,” allows ...
Commentary
Harris’s Farcical Price Control Schemes
Karl Marx famously said that history repeats itself first as tragedy, then as farce. Vice President Kamala Harris is bringing that aphorism to life by putting price controls at the center of her economic agenda. Despite centuries of evidence that such controls invariably lead to shortages, rationing and general economic ...
Commentary
American Healthcare Broken? Says Who?
A new study from the Commonwealth Fund ranks the U.S. health system dead last among 10 developed nations. But is healthcare in the United States really that bad? A close look at the data suggests otherwise. Read the full article in Newsmax.
Biosimilars
The Biosimilar Promise
Biosimilars Often Reduce Prices by 50 Percent or More
Biosimilars Often Reduce Prices by 50 Percent or More By Wayne Winegarden | October 1, 2024 READ PDF Executive Summary In the competitive biologic markets, biosimilars have reduced average prices by 56 percent. The lower prices have reduced total expenditures by 51 percent in the competitive biologic markets even though ...
Commentary
A British Lord’s Warning: Steer Clear of Single-Payer Healthcare
Two hundred and fifty years ago, a group of Americans sounded the alarm about the oppressive government policies being propagated by British lords. Today, the tables have turned. This month, Lord Ara Darzi presented the United Kingdom’s Secretary of State for Health and Social Care with a devastating report on the state ...
Commentary
Women, Children, Disabled Pay The Price For Obamacare’s Medicaid Expansion
Obamacare greatly expanded Medicaid eligibility. As a result, about 20 million able-bodied, working-age adults who were previously ineligible are now enrolled in the program. But as a new report from the Paragon Health Institute makes clear, their gains have come at the expense of the pregnant women, children, and people ...
Learn more about how price fixing stifles innovation
New Schizophrenia Drug Represents Promise Of Pharmaceutical Innovation
Late last month, the U.S. Food and Drug Administration approved Bristol Myers Squibb’s KarXT, a treatment for schizophrenia. The drug, which will be marketed under the brand name Cobenfy, is promising not just because it is effective at treating the debilitating mental health condition. It also seems not to have the potentially harmful side ...
Learn more about healthcare reform
Vance’s Critics Wrong: No Need to Fear High-Risk Pools
Following the recent vice-presidential debate, Sen. J.D. Vance, R-Ohio, continues to face attacks on his ideas for covering people with pre-existing conditions. Vance’s critics call his proposal — which would separate out sicker patients into a separate high-risk insurance pool — inhumane and impractical. As Arthur Caplan, the head of medical ethics at NYU ...
Learn more about how price controls are driving physician shortages
Price Controls Are Harming Doctors
Whether its pharmaceuticals or health insurance, Vice President Kamala Harris appears to have only one healthcare policy – impose price controls. The untenable financial position of many doctors and private doctor practices due to tightening Medicare reimbursement rates exemplifies the folly of her preferred approach. As I document in a recent ...
Learn how Vance's suggestion would benefit consumers
Vance’s Argument on Preexisting Conditions a Sure Winner
When asked how people with pre-existing conditions would fare under a Trump-Vance administration during last week’s vice-presidential debate, Sen. J.D. Vance, R-Ohio, was unequivocal. “Well, of course, we’re going to cover Americans with pre-existing conditions.” The question was prompted by Vance’s statement last month that the Republican ticket would consider creating different risk ...
How The Hospital Industrial Complex Robs Poor Patients
Pharmaceutical leader Johnson & Johnson recently unleashed a firestorm in Washington after it proposed a change to how it offers discounted prices on two drugs in a little-known, but enormous, federal program that’s hurting the low-income patients it was created to help. That program, known as the “340B Drug Pricing Program,” allows ...
Harris’s Farcical Price Control Schemes
Karl Marx famously said that history repeats itself first as tragedy, then as farce. Vice President Kamala Harris is bringing that aphorism to life by putting price controls at the center of her economic agenda. Despite centuries of evidence that such controls invariably lead to shortages, rationing and general economic ...
American Healthcare Broken? Says Who?
A new study from the Commonwealth Fund ranks the U.S. health system dead last among 10 developed nations. But is healthcare in the United States really that bad? A close look at the data suggests otherwise. Read the full article in Newsmax.
The Biosimilar Promise
Biosimilars Often Reduce Prices by 50 Percent or More
Biosimilars Often Reduce Prices by 50 Percent or More By Wayne Winegarden | October 1, 2024 READ PDF Executive Summary In the competitive biologic markets, biosimilars have reduced average prices by 56 percent. The lower prices have reduced total expenditures by 51 percent in the competitive biologic markets even though ...
A British Lord’s Warning: Steer Clear of Single-Payer Healthcare
Two hundred and fifty years ago, a group of Americans sounded the alarm about the oppressive government policies being propagated by British lords. Today, the tables have turned. This month, Lord Ara Darzi presented the United Kingdom’s Secretary of State for Health and Social Care with a devastating report on the state ...
Women, Children, Disabled Pay The Price For Obamacare’s Medicaid Expansion
Obamacare greatly expanded Medicaid eligibility. As a result, about 20 million able-bodied, working-age adults who were previously ineligible are now enrolled in the program. But as a new report from the Paragon Health Institute makes clear, their gains have come at the expense of the pregnant women, children, and people ...
